Notably, the ability of erdafitinib to sensitize cancer cells to chemotherapies was solely dependent on ABCB1 since this TKI has no significant effect on ABCG2-mediated resistance to topotecan or SN-38, known substrates for ABCG2 [165]. The gene discussed is ABCG2; the disease is cancer.